Company intelligence / Profile preview
Tianjin Weikai Bioengineering
Tianjin, Tianjin, Chinaweikaibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tianjin Weikai Bioengineering is a clinical-stage biotechnology company based in China, dedicated to the research, development, and commercialization of innovative cell therapies. The company primarily focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies for the treatment of hematological cancers and solid tumors. Its lead program, WK01, is a CD19-targeted CAR-T therapy currently being evaluated in clinical trials for B-cell malignancies. Weikai Bioengineering maintains integrated R&D and GMP-compliant manufacturing capabilities in Tianjin to support its growing pipeline of next-generation immunotherapies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapyT cell receptor engineered T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tianjin Weikai Bioengineering.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Weikai Bioengineering.